Insider Transactions in Q1 2026 at Nuvalent, Inc. (NUVL)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2026
|
James Richard Porter President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+12.46%
|
-
|
|
Jan 07
2026
|
Alexandra Balcom Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+14.99%
|
-
|
|
Jan 07
2026
|
Christopher Durant Turner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+19.42%
|
-
|
|
Jan 07
2026
|
Deborah Ann Miller Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+22.69%
|
-
|
|
Jan 07
2026
|
Darlene Noci Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+23.14%
|
-
|
|
Jan 07
2026
|
Henry E. Pelish Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+17.35%
|
-
|
|
Jan 06
2026
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
9,543
-1.11%
|
$925,671
$97.49 P/Share
|
|
Jan 06
2026
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,181
-1.26%
|
$308,557
$97.49 P/Share
|
|
Jan 06
2026
|
Christopher Durant Turner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,181
-1.85%
|
$308,557
$97.49 P/Share
|
|
Jan 06
2026
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,589
-1.96%
|
$251,133
$97.49 P/Share
|
|
Jan 06
2026
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,181
-2.47%
|
$308,557
$97.49 P/Share
|
|
Jan 06
2026
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,664
-1.31%
|
$258,408
$97.49 P/Share
|
|
Jan 05
2026
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
17,890
-1.49%
|
$1,735,330
$97.35 P/Share
|
|
Jan 05
2026
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,236
-1.21%
|
$410,892
$97.35 P/Share
|
|
Jan 05
2026
|
Christopher Durant Turner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,236
-1.73%
|
$410,892
$97.35 P/Share
|
|
Jan 05
2026
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,363
-2.29%
|
$423,211
$97.35 P/Share
|
|
Jan 05
2026
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,236
-2.27%
|
$410,892
$97.35 P/Share
|
|
Jan 05
2026
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,496
-0.89%
|
$242,112
$97.35 P/Share
|
|
Jan 02
2026
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-5.92%
|
$1,000,000
$100.76 P/Share
|
|
Jan 02
2026
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+14.47%
|
$180,000
$18.93 P/Share
|